Auris Medical Holding AG [NASDAQ:EARS]: Analyst Rating and Earnings
Stock market traders oftentimes pay a lot of attention to what top analysts say regarding a potential investment. Regarding Auris Medical Holding AG [EARS], the latest average analyst recommendation we can see is from the quarter closing in December. On average, stock market experts give EARS an Outperform rating. The average 12-month price forecast for this stock is $2.50, with the high estimate being $2.50, the low estimate being $2.50 and the median estimate amounting to $2.50. This is compared to its latest closing price of $0.45.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Auris Medical Holding AG [EARS] is sitting at 2.00. This is compared to 1 month ago, when its average rating was 2.00.
Pay attention for this company’s financial results, of which the next release is scheduled to happen on Thu 28 Mar (In 75 Days).
Fundamental Analysis of Auris Medical Holding AG [EARS]
This company’s Return on Total Capital is -144.52Its Return on Equity is -424.05, and its Return on Assets is -92.18. These metrics show a mixed bag, which means that this investment’s attractiveness can be quickly increased or decreased in the short term, depending on future updates EARS financial performance.
Similarly, its Total Debt to Total Capital is 127.15, while its Total Debt to Total Assets stands at 56.12.
What about valuation? This company’s Enterprise Value to EBITDA is -0.47. Total Debt to Enterprise Value stands at 0.50.
This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.52 and its Current Ratio is 1.52. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Auris Medical Holding AG [EARS] has 31.22M shares outstanding, amounting to a total market cap of $13.27M. Its stock price has been found in the range of 0.23 to 5.50. At its current price, it has moved by -92.27% from its 52-week high, and it has moved 84.78% from its 52-week low.
This stock’s Beta value is currently -0.63, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 42.04. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Auris Medical Holding AG [EARS] a Reliable Buy?
Auris Medical Holding AG [EARS] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.